Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | SMARCA2 | P51531 | 4/20 | 0.42 |
| ▸ | SMARCA4 | P51532 | 4/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.42 |
| ▸ | PBRM1 | Q86U86 | 3/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.40 |
| ▸ | RELA | Q04206 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | KMO | O15229 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18038685 | 0.80 | ADORA2A (0.50) | SMARCA2SMARCA4NR1I2PBRM1BRD4 | |
| SCHEMBL29175911 | 0.76 | RAB9A (0.37) | HSD17B10RAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL22313076 | 0.73 | L3MBTL1 (0.33) | HSD17B10SMN1; SMN2MAPTALDH1A1MEN1 | |
| SCHEMBL22313786 | 0.73 | KCNH2 (0.34) | SMN1; SMN2MAPTALDH1A1LMNAGAA | |
| SCHEMBL22313784 | 0.73 | SLC6A2 (0.37) | RAB9ASMN1; SMN2MAPTNPC1MEN1 | |
| SCHEMBL2404530 | 0.73 | NPC1 (0.50) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL22313846 | 0.73 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL10973695 | 0.72 | KMT2A (0.49) | SMARCA2SMARCA4NR1I2PBRM1BRD4 | |
| SCHEMBL29943290 | 0.72 | SMARCA2 (0.54) | SMARCA2SMARCA4NR1I2PBRM1BRD4 | |
| SCHEMBL18038669 | 0.72 | SMARCA2 (0.54) | SMARCA2SMARCA4NR1I2PBRM1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | claimed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | claimed |
| EP-3262036-A1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2018-01-03 | — | — | EP | claimed |
| WO-2016138114-A1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-09-01 | — | — | WO | claimed |
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-107531668-B | Therapeutic pyridazine compounds and uses thereof | 基因泰克公司 | 2021-10-29 | — | — | CN | disclosed |
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| EP-3262036-A1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016138114-A1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| WO-2016138114-A1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | FYN 3866/4885SMARCA2 10/4885SMARCA4 3/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | FYN 3866/4885SMARCA2 10/4885SMARCA4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.